
NSCLC market set to double by 2036 as biomarker-driven treatments advance at ESMO 2026.
The non-small cell lung cancer (NSCLC) market across seven major countries is projected to grow from USD 33 billion in 2025 to about USD 67 billion by 2036, driven by advances in biomarker-guided therapies highlighted at the ESMO 2026 Congress. Key P...





